RANI
Neutral signalScored 2026-07-29 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Rani Therapeutics Holdings, Inc.
- Nom
- Rani Therapeutics Holdings, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $39.6M
- Employés
- 70
- PDG
- Talat Imran
- Site web
- https://www.ranitherapeutics.com
- Marché
- APLTCRBPCRDFCYBNELTXIPHA
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 71 000 titres (~50 033,00 $ US)
- Insiders
- IMRAN MIR AImran Talat
- Total bought
-
$50,033
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-21
- Last synced
-
2026-10-19 21:57:15
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-07-29 Drivers: fundamentals. Moteurs : fondamentaux.
RANI presents a genuine event-driven catalyst — a timely insider cluster buy following positive Phase 1a RT-114 obesity data (+150% bioavailability vs.
The first sentence of the analysis written for RANI on 2026-07-29 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.21 · operating margin -2346% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 44.9% | 100.0% | 0.0% | 0.0% | 100.0% | |
| Ebit Margin | -2330.6% | -5014.7% | 0.0% | 0.0% | -1935.3% | |
| Ebitda Margin | -2275.5% | -4914.7% | 0.0% | 0.0% | -1917.0% | |
| Operating Profit Margin | -2346.0% | -5186.2% | 0.0% | 0.0% | -1899.1% | |
| Pretax Profit Margin | -2507.7% | -2920.0% | 0.0% | 0.0% | -1952.4% | |
| Continuous Operations Profit Margin | -2507.7% | -5504.3% | 0.0% | 0.0% | -1953.9% | |
| Net Profit Margin | -1817.1% | -2920.0% | 0.0% | 0.0% | -306.6% | |
| Bottom Line Profit Margin | -1817.1% | -2920.0% | 0.0% | 0.0% | -306.6% | |
| Current Ratio | 4.209 | 1.495 | 6.365 | 20.960 | 45.301 | |
| Quick Ratio | 4.209 | 1.495 | 6.365 | 20.960 | 45.301 | |
| Solvency Ratio | -1.682 | -0.875 | -1.021 | -0.883 | -2.967 | |
| Cash Ratio | 1.470 | 0.189 | 0.734 | 5.609 | 44.490 | |
| Price To Earnings Ratio | -3.000 | -1.305 | -2.496 | -4.609 | -38.929 | |
| Price To Earnings Growth Ratio | 0.053 | 0.062 | -0.639 | -0.023 | 0.770 | |
| Forward Price To Earnings Growth Ratio | 0.053 | 0.062 | -0.639 | -0.023 | 0.770 | |
| Price To Earnings Diluted Ratio | -3.000 | -1.305 | -2.496 | -4.609 | -38.929 | |
| Price To Earnings Diluted Growth Ratio | 0.053 | 0.062 | -0.639 | -0.023 | 0.770 | |
| Price To Book Ratio | 2.705 | 19.584 | 6.581 | 3.813 | 6.736 | |
| Price To Sales Ratio | 54.676 | 37.950 | 0.000 | 0.000 | 117.549 | |
| Price To Free Cash Flow Ratio | -4.749 | -1.091 | -1.614 | -2.919 | -9.752 | |
| Price To Operating Cash Flow Ratio | -4.771 | -1.099 | -1.653 | -3.021 | -9.905 | |
| Debt To Assets Ratio | 0.074 | 0.811 | 0.520 | 0.280 | 0.000 | |
| Debt To Equity Ratio | 0.131 | 14.914 | 2.339 | 0.820 | 0.000 | |
| Debt To Capital Ratio | 0.116 | 0.937 | 0.701 | 0.450 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.076 | 0.828 | 0.656 | 0.442 | 0.000 | |
| Financial Leverage Ratio | 1.776 | 18.391 | 4.501 | 2.931 | 2.620 | |
| Working Capital Turnover Ratio | 0.065 | 0.039 | 0.000 | 0.000 | 0.029 | |
| Operating Cash Flow Ratio | -1.477 | -1.785 | -6.413 | -9.660 | -12.214 | |
| Operating Cash Flow Sales Ratio | -11.460 | -34.529 | 0.000 | 0.000 | -11.868 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.008 | 1.024 | 1.035 | 1.016 | |
| Debt Service Coverage Ratio | -12.853 | -3.848 | -6.209 | -57.633 | -111.856 | |
| Interest Coverage Ratio | -13.251 | -10.593 | -12.999 | -59.245 | -110.727 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -2.366 | -10.463 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -4.334 | -1.195 | -1.702 | -1.540 | 0.000 | |
| Capital Expenditure Coverage Ratio | -212.659 | -132.448 | -41.689 | -28.731 | -63.725 | |
| Dividend Paid And Capex Coverage Ratio | -212.659 | -132.448 | -41.689 | -28.731 | -63.725 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.018 | -1.286 | -1.757 | -2.331 | -3.877 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 44.9% | ▼-55.1% | ▼-4.1% |
| Ebit Margin | -2330.6% | ▲2684.1% | ▼-474.5% |
| Ebitda Margin | -2275.5% | ▲2639.2% | ▼-454.1% |
| Operating Profit Margin | -2346.0% | ▲2840.2% | ▼-459.7% |
| Pretax Profit Margin | -2507.7% | ▲412.4% | ▼-1031.6% |
| Continuous Operations Profit Margin | -2507.7% | ▲2996.6% | ▼-514.5% |
| Net Profit Margin | -1817.1% | ▲1103.0% | ▼-808.3% |
| Bottom Line Profit Margin | -1817.1% | ▲1103.0% | ▼-808.3% |
| Current Ratio | 4.209 | ▲2.713 | ▼-11.457 |
| Quick Ratio | 4.209 | ▲2.713 | ▼-11.457 |
| Solvency Ratio | -1.682 | ▼-0.807 | ▼-0.196 |
| Cash Ratio | 1.470 | ▲1.280 | ▼-9.029 |
| Price To Earnings Ratio | -3.000 | ▼-1.695 | ▲7.068 |
| Price To Earnings Growth Ratio | 0.052 | ▼-0.009 | ▲0.008 |
| Forward Price To Earnings Growth Ratio | 0.052 | ▼-0.009 | ▲0.008 |
| Price To Earnings Diluted Ratio | -3.000 | ▼-1.695 | ▲7.068 |
| Price To Earnings Diluted Growth Ratio | 0.052 | ▼-0.009 | ▲0.008 |
| Price To Book Ratio | 2.705 | ▼-16.880 | ▼-5.179 |
| Price To Sales Ratio | 54.676 | ▲16.727 | ▲12.641 |
| Price To Free Cash Flow Ratio | -4.749 | ▼-3.658 | ▼-0.724 |
| Price To Operating Cash Flow Ratio | -4.771 | ▼-3.672 | ▼-0.681 |
| Debt To Assets Ratio | 0.074 | ▼-0.737 | ▼-0.263 |
| Debt To Equity Ratio | 0.131 | ▼-14.783 | ▼-3.510 |
| Debt To Capital Ratio | 0.116 | ▼-0.822 | ▼-0.325 |
| Long Term Debt To Capital Ratio | 0.076 | ▼-0.752 | ▼-0.324 |
| Financial Leverage Ratio | 1.776 | ▼-16.615 | ▼-4.268 |
| Working Capital Turnover Ratio | 0.065 | ▲0.026 | ▲0.038 |
| Operating Cash Flow Ratio | -1.477 | ▲0.307 | ▲4.833 |
| Operating Cash Flow Sales Ratio | -11.460 | ▲23.069 | ▲0.112 |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | ▼-0.003 | ▼-0.013 |
| Debt Service Coverage Ratio | -12.853 | ▼-9.005 | ▲25.627 |
| Interest Coverage Ratio | -13.252 | ▼-2.659 | ▲28.112 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲2.366 | ▲2.566 |
| Operating Cash Flow Coverage Ratio | -4.334 | ▼-3.139 | ▼-2.580 |
| Capital Expenditure Coverage Ratio | -212.659 | ▼-80.211 | ▼-116.809 |
| Dividend Paid And Capex Coverage Ratio | -212.659 | ▼-80.211 | ▼-116.809 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.018 | ▼-0.732 | ▲0.236 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $89.3M | $39.0M | $84.7M | $140.5M | $319.4M | |
| Enterprise value | $75.0M | $65.0M | $108.9M | $143.7M | $201.9M | |
| EV / Sales | 45.92x | 63.19x | 0.00x | 0.00x | 74.32x | |
| EV / Op. cash flow | -4.01x | -1.83x | -2.13x | -3.09x | -6.26x | |
| EV / Free cash flow | -3.99x | -1.82x | -2.08x | -2.99x | -6.17x | |
| EV / EBITDA | -2.02x | -1.29x | -1.76x | -2.33x | -3.88x | |
| Net debt / EBITDA | 0.39x | -0.51x | -0.39x | -0.05x | 2.25x | |
| Current ratio | 4.21x | 1.50x | 6.37x | 20.96x | 45.30x | |
| Income quality | 0.63x | 0.63x | 1.51x | 0.73x | 3.87x | |
| Graham net-net | $1 | -$0 | $1 | $3 | $6 | |
| Tax burden | 72.5% | 100.0% | 50.0% | 48.3% | 15.7% | |
| Interest burden | 107.6% | 58.2% | 108.1% | 101.7% | 100.9% | |
| Working capital | $40.7M | $9.9M | $42.9M | $96.1M | $117.0M | |
| Invested capital | $45.7M | $16.5M | $49.7M | $103.2M | $121.6M | |
| Return on assets | -50.6% | -81.9% | -58.7% | -28.3% | -6.7% | |
| Operating ROA | -80.4% | -112.8% | -79.7% | -54.6% | -50.7% | |
| Return on tangible assets | -50.6% | -81.9% | -58.7% | -28.3% | -6.7% | |
| Return on equity | -89.9% | -1506.9% | -264.0% | -83.0% | -17.6% | |
| Return on invested capital | -80.6% | -160.6% | -119.0% | -60.9% | -42.4% | |
| Return on capital employed | -83.4% | -318.4% | -132.4% | -61.5% | -42.4% | |
| Earnings yield | -33.2% | -76.9% | -40.1% | -21.8% | -2.6% | |
| Free cash flow yield | -21.1% | -91.7% | -62.0% | -34.3% | -10.3% | |
| Capex / Op. cash flow | -0.5% | -0.8% | -2.4% | -3.5% | -1.6% | |
| Capex / Depreciation | 9.8% | 26.1% | 149.5% | 295.4% | 101.8% | |
| Capex / Sales | 5.4% | 26.1% | 0.0% | 0.0% | 18.6% | |
| SG&A / Sales | 1208.7% | 2329.4% | 0.0% | 0.0% | 1024.4% | |
| R&D / Sales | 1237.3% | 2595.5% | 0.0% | 0.0% | 974.7% | |
| Stock comp / Sales | 722.5% | 1559.4% | 0.0% | 0.0% | 831.6% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 456d | 152d | 0d | 0d | 0d | |
| Days payables outstanding | 125d | 0d | 288d | 0d | 0d | |
| Operating cycle | 456d | 152d | 0d | 0d | 0d | |
| Cash conversion cycle | 331d | 152d | -288d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-13 Rani Therapeutics to Participate in the Chardan Healthcare Conference SAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company''s management team will participate in a fireside chat at the upcoming Chardan Healthcare Conference. Details below:
- 2026-10-05 Rani Therapeutics Announces Acceptance into U.S. FDA''s Emerging Technology Program (ETP) ~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~ ~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~
- 2026-09-08 Rani Therapeutics to Participate in Upcoming September Conferences SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company''s management team will participate in the upcoming September conferences.
- 2026-08-16 Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity.
- 2026-08-13 Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update ~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~ ~ Completed a $20 million registered direct offering ~ ~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill® platform ~ ~ Appointed Nicholas Maestas as Chief Financial Officer and Michelle Gilson to Board of Directors ~ SAN JOSE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
- 2026-08-10 Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company''s management team will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. Details below:
- 2026-07-20 Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani''s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.